1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Pharmaron Beijing Co., Ltd. Class A

Pharmaron Beijing Co., Ltd. Class A

2.96
EUR
-0.14
(-4.52%)
0.10EPS
20.20P/E
6.33BMarket Cap
Oct 27Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.62
0.63
0.87
1.04
1.32
1.53
1.74
2.52
3.49
3.93
4.19
4.83
7.15
Basic EPS, GAAP
0.04
0.04
0.09
0.1
0.15
0.22
0.4
0.56
0.47
0.55
0.61
0.57
0.8
Free Cash Flow per Basic Share
-0.14
-0.02
-0.44
-0.17
0.07
0.07
0.11
-0.01
-0.27
-0.04
0.18
0.19
- -
Dividend per Share
0.03
0.01
0.01
0.03
0.03
0.06
0.05
0.1
0.14
0.15
0.18
0.18
0.09
Book Value per Share
0.53
0.35
0.8
0.91
1.05
2.62
3
3.42
3.56
4.24
4.62
5.11
5.37
Tangible Book Value per Share
0.48
0.3
0.79
0.71
0.81
2.41
2.41
2.48
2.38
3.04
3.42
3.49
3.8
Basic Weighted Avg Shares
488
1,778
1,884
2,206
2,202
2,462
2,947
2,951
2,938
2,936
2,932
2,919
2,091
Sales/Revenue/Turnover
790
1,128
1,634
2,294
2,908
3,757
5,134
7,444
10,266
11,538
12,276
14,095
14,947
Operating Margin (%)
5.25
7.57
11.5
15.79
15.97
18.74
21.13
20.49
17.05
15.89
15.19
15.78
15.37
Depreciation Expense
51
64
93
145
262
318
375
498
696
927
1,049
1,181
- -
Net Income, GAAP
21
74
177
231
333
547
1,172
1,661
1,375
1,601
1,793
1,664
1,669
Effective Tax Rate (%)
27.37
15.62
17.53
18.49
15.21
16.11
13.07
15.22
18.86
13.93
18.03
18.69
19.66
Profit Margin (%)
2.66
6.55
10.83
10.06
11.45
14.56
22.84
22.31
13.39
13.88
14.61
11.8
11.17
Working Capital
-239
-530
436
137
-32
4,675
3,559
5,662
2,624
7,220
3,384
-586
147
LT Debt
5
3
315
829
1,021
673
581
4,708
5,215
8,785
4,779
2,151
2,273
Total Equity
258
168
1,763
2,010
2,327
7,838
8,934
10,295
10,840
13,238
14,223
15,739
17,051
Return on Invested Capital (%)
- -
14.5
11.21
7.46
9.11
8.24
12.18
12.65
8.38
7.92
7.94
7.26
7.06
Return on Capital (%)
- -
21.34
13.83
9.96
10.86
9.87
12.92
13.87
9.42
8.91
9.61
8.98
8.63
Return on Common Equity (%)
- -
34.61
18.32
12.28
15.45
10.86
14.09
17.48
13.3
13.86
13.7
11.6
10.98

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,889
4,861
4,681
LT Borrowings
1,772
1,844
1,920
LT Finance Leases
379
396
353
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,946
3,043
3,043
Market Capitalization
50,843
49,987
49,067

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
7,778
9,051
8,870
Cash, Cash Equivalents & STI
1,732
2,977
2,452
Accounts Receivable, Net
2,707
2,661
2,856
Inventories
1,472
1,694
1,935
Total Current Liabilities
8,364
8,370
8,722
Payables & Accruals
- -
- -
- -
ST Debt
4,889
4,861
4,681
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
128.83%
12.15%
10.66%
Free Cash Flow
323.94%
289.49%
2.98%
Net Income, GAAP
43.86%
9.14%
-7.22%
Sales/Revenue/Turnover
29.44%
23.3%
14.82%
Total Cash Common Dividend
60.27%
36.43%
-2.06%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,671
2,934
3,213
3,458
12,276
2025
3,099
3,342
- -
4,009
14,095
2026
3,578
4,017
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.49
0.17
0.21
0.61
2025
0.1
0.22
- -
0.29
0.57
2026
0.11
0.23
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.19
0.06
0.02
0.18
2025
0.01
0.03
- -
0.03
0.18
2026
0.02
0.03
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Bo Liang Lou
Full Time Employees
25,088
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building 1 Beijing BJ China 100176
IPO Date
Jan 28, 2019
Website
pharmaron.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Pharmaron Beijing Co., Ltd. (300759.SZ/3759.HK) provides fully integrated research, development and manufacturing services for the life sciences industry, spanning drug discovery, preclinical and clinical development across small molecules, biologics and cell and gene therapy products. The company offers laboratory services including medicinal and synthetic chemistry, chemistry for new modalities such as oligonucleotides, peptides, antibodies and antibody-drug conjugates, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, computer-aided drug design, structural biology, in vitro biology, DMPK, in vivo pharmacology and compound management; chemistry, manufacturing and controls services encompassing API process development and production, material science, pre-formulation, formulation development and manufacturing, analytical development; clinical development services such as integrated radiolabelled science, early-stage and Phase I-IV clinical trials, clinical trial recruitment; safety assessment, integrated drug discovery and bioanalysis; and biologics and cell and gene therapy services comprising biologics laboratory and CDMO, cell and gene therapy laboratory and gene therapy CDMO. Founded in 2004 and headquartered in Beijing, China, Pharmaron operates over 21 R&D centers and manufacturing sites with more than 22,000 employees, serving clients in North America, Europe, Japan, Mainland China and internationally from facilities in China, the U.S. and the U.K. In October 2025, the company entered a definitive share purchase agreement to acquire 82.54% equity interest in Biortus Biosciences Co., Ltd., enhancing its capabilities in structural biology, complex protein production and analysis, protein science, biological assays, compound screening, protein crystallization, structure analysis and structure-based drug design to strengthen its end-to-end multi-modality platform.